Is Crestor Better Than Lipitor for Cholesterol?

Rosuvastatin (sold as Crestor) lowers LDL cholesterol more effectively than atorvastatin (Lipitor) at comparable doses, with roughly an 8 percent greater reduction milligram for milligram. But cholesterol management is not just a numbers game, and the question of which statin is “better” gets complicated fast. The two drugs differ in how the body processes them, how they affect the kidneys, how they interact with other medications, and whether harder outcomes like heart attacks and strokes actually diverge between them.

LDL Lowering Power

On raw cholesterol-lowering ability, rosuvastatin wins. A head-to-head trial across multiple dose levels found that rosuvastatin produced about an 8 percent greater drop in LDL at any given dose compared with atorvastatin.¹ In patients with type 2 diabetes, rosuvastatin cut LDL by about 52 percent versus 46 percent for atorvastatin after dose adjustments.²

A large meta-analysis called VOYAGER, which pooled data from many statin trials, put this into practical terms. Rosuvastatin at 10 mg lowered LDL by about 44 percent. To get that same reduction with atorvastatin, you would need roughly 29 mg, a dose that does not actually exist as a standard tablet. At the top end, rosuvastatin 40 mg cut LDL by about 55 percent, a level that even the maximum 80 mg dose of atorvastatin could not match.³ Pooled data from early trials also showed that at the common starting dose of 10 mg, significantly more rosuvastatin patients hit their cholesterol goals compared with atorvastatin patients (76 percent versus 53 percent by U.S. treatment guidelines).⁴

Beyond LDL: HDL and Triglycerides

LDL gets most of the attention, but doctors also care about HDL (the “good” cholesterol) and triglycerides. A 2025 systematic review and meta-analysis compared the two drugs across both measures. Rosuvastatin raised HDL by about 3.9 mg/dL on average, while atorvastatin raised it by about 1.9 mg/dL. For triglyceride reduction, rosuvastatin lowered levels by roughly 32 mg/dL versus about 25 mg/dL for atorvastatin.⁵ These are modest differences, and whether they translate into meaningful clinical benefits on their own is debatable. But for patients who need improvement across the full lipid panel, rosuvastatin has a slight edge on paper.

Do Those Lab Numbers Translate Into Fewer Heart Attacks?

This is where the story gets more interesting, and honestly less clear-cut. You might assume that the drug lowering cholesterol more aggressively would prevent more cardiovascular events. The evidence is mixed.

A large observational study using data from nearly 286,000 participants across two databases found that rosuvastatin was associated with lower six-year all-cause mortality compared with atorvastatin, with a cumulative incidence difference of about one to one and a half percentage points. Rosuvastatin also showed lower risks for major cardiovascular events and other adverse outcomes in that analysis.⁶

But the LODESTAR trial, a randomized study in patients with coronary artery disease, told a different story. Over three years, the primary composite outcome (death, heart attack, stroke, or need for a new heart procedure) occurred in about 8.7 percent of rosuvastatin patients and 8.2 percent of atorvastatin patients. That difference was not statistically meaningful. Death rates, heart attack rates, and stroke rates were all similar between the two groups.⁷ The same picture emerged for artery plaque: a study using imaging to compare plaque changes found no significant difference between the two drugs in how much arterial plaque shrank over time.⁸

How do you reconcile these findings? Observational studies, even very large ones, cannot fully account for the fact that doctors may choose one statin over the other for reasons that also affect outcomes. Randomized trials like LODESTAR do a better job of isolating the drug’s effect from everything else. The current weight of evidence suggests that both drugs produce similar cardiovascular protection when dosed to achieve similar cholesterol levels.

Why They Behave Differently in the Body

Rosuvastatin and atorvastatin belong to the same drug class but differ in a basic chemical property. Rosuvastatin dissolves more readily in water (hydrophilic), while atorvastatin dissolves more readily in fats (lipophilic).⁹ This distinction matters because it shapes which tissues the drug enters and how the body breaks it down.

Lipophilic statins like atorvastatin can pass easily into cells throughout the body, including muscle and brain cells. Hydrophilic statins like rosuvastatin tend to concentrate more in the liver, which is where cholesterol production actually happens. In theory, that liver selectivity could mean fewer off-target effects elsewhere. In practice, both drugs have similar overall tolerability profiles, though the distinction becomes relevant in specific scenarios like drug interactions and kidney effects.

Atorvastatin is broken down extensively by a family of liver enzymes called CYP3A4, the same enzymes that process a huge number of other medications. Rosuvastatin largely bypasses this system.¹⁰ That makes rosuvastatin less prone to drug interactions, which matters a lot if you are taking medications like certain antifungals, HIV protease inhibitors, or some heart rhythm drugs that compete for the same enzymes.¹¹

Muscle Side Effects

Muscle pain is the most common complaint that drives people to stop taking statins. Many patients and even some clinicians assume one statin is gentler on muscles than another, but the data does not clearly support that. A large network meta-analysis of 135 randomized trials found that individual statins were not significantly different from placebo in terms of muscle pain or muscle enzyme elevations. Higher doses of both atorvastatin and rosuvastatin did lead to more people discontinuing treatment.¹²

An observational cohort study comparing muscular events between the two drugs at equivalent doses found a hazard ratio of 1.17 for rosuvastatin versus atorvastatin, meaning a very slight numerical increase in muscle events with rosuvastatin, but this was not statistically significant. Rates were roughly 18 versus 15 muscle events per 1,000 person-years. Both rates were highest in the first 90 days and dropped off after that.¹³ If you develop muscle symptoms on one, switching to the other is a reasonable strategy, but there is no strong evidence that one is systematically easier on muscles than the other.

The Diabetes Question

Both rosuvastatin and atorvastatin, particularly at high doses, increase the risk of developing new-onset diabetes. This is a class effect shared across potent statins, not unique to either drug.¹⁴ But there is a nuance worth knowing about.

A post-hoc analysis from the LODESTAR trial focused specifically on patients receiving high-intensity doses. Overall, rates of new diabetes were not significantly different (about 11 percent with rosuvastatin versus 9 percent with atorvastatin). However, among patients whose LDL was driven below 70 mg/dL, rosuvastatin was associated with a meaningfully higher diabetes risk: roughly 14 percent versus 8 percent.¹⁵ This suggests that when very aggressive LDL lowering is the goal, the choice of statin may matter for diabetes risk. For patients already on the borderline of diabetes, this is a conversation worth having with a doctor.

Kidney Effects Favor Atorvastatin

This is one area where atorvastatin has a clearer advantage. The difference is relevant enough that kidney specialists pay close attention to which statin they prescribe.

The PLANET I trial studied patients with diabetes and proteinuria (protein in the urine, a sign of kidney stress). High-dose atorvastatin significantly reduced proteinuria over a year, while neither dose of rosuvastatin did. When data from a companion trial in non-diabetic kidney patients was combined, atorvastatin lowered proteinuria about 16 to 18 percent more than rosuvastatin.¹⁶ A study in patients with diabetes also found faster kidney function decline in the rosuvastatin group, with about a 60 percent higher odds of rapid decline after adjusting for other factors.¹⁷

A large target trial emulation study in Chinese patients with diabetes found that rosuvastatin and atorvastatin carried similar risks for end-stage kidney disease. But rosuvastatin was associated with a higher risk of developing new-onset albuminuria, another marker of early kidney damage, with about a 30 percent higher risk after accounting for time-varying drug exposure.¹⁸ This doesn’t mean rosuvastatin is dangerous for kidneys in the general population, but for patients who already have kidney disease or are at high risk for it, atorvastatin appears to be the safer choice.

Inflammation Beyond Cholesterol

Statins do more than just lower cholesterol. They also reduce inflammation, which plays a significant role in cardiovascular disease. Both rosuvastatin and atorvastatin lower C-reactive protein (CRP), a common blood marker of inflammation. In a study of acute coronary syndrome patients, both drugs substantially reduced CRP over four weeks, but rosuvastatin lowered it a bit more.¹⁹

A systematic review and meta-analysis of head-to-head randomized trials largely confirmed this, finding a small but statistically significant edge for rosuvastatin in CRP reduction once an outlier study was removed. The magnitude was modest. For other inflammatory markers like IL-6 and TNF-alpha, no significant difference emerged between the two drugs.²⁰ Whether rosuvastatin’s slight CRP advantage matters clinically beyond what it achieves through LDL lowering is an open question.

CoQ10 and Exercise

Statins can reduce levels of coenzyme Q10 (ubiquinol), a molecule involved in cellular energy production. Some researchers have speculated that CoQ10 depletion may contribute to the muscle symptoms patients report. In one study comparing the two drugs in patients with coronary artery disease, atorvastatin significantly reduced blood ubiquinol levels, while rosuvastatin did not. The combination of rosuvastatin with regular exercise preserved CoQ10 levels and was associated with an increase in HDL.²¹ This is a single study and not enough to draw sweeping conclusions, but it adds to the picture of how the two drugs differ in their off-target effects.

Genetic Variation and Dose Adjustments

One underappreciated difference between the two drugs involves how genetics affect blood levels. Rosuvastatin relies heavily on specific drug transporters in the body, and genetic variants in these transporters are distributed unevenly across ethnic groups. Studies have consistently found that people of East Asian descent have roughly 65 to 100 percent higher blood concentrations of rosuvastatin compared with white populations at the same dose.²² This is why the FDA-approved labeling for rosuvastatin recommends starting at a lower dose (5 mg) in Asian patients.

A follow-up study showed that this difference was driven largely by variants in two drug transporter genes. When researchers compared Asian and white volunteers who shared the same transporter gene variants, the drug exposure was essentially identical.²³ Atorvastatin is also affected by transporter genetics, but the ethnic difference in blood levels is less pronounced. For patients of East Asian or South Asian descent, this pharmacogenetic wrinkle can influence which statin a doctor chooses or what dose they start with.

Drug Interactions in Practice

Because atorvastatin relies on CYP3A4 enzymes for metabolism, taking it alongside drugs that inhibit those enzymes can significantly raise atorvastatin blood levels and increase the risk of side effects. Common culprits include clarithromycin (an antibiotic), itraconazole (an antifungal), certain HIV medications, and even large amounts of grapefruit juice. Rosuvastatin, by contrast, is not significantly metabolized by CYP3A4 and faces far fewer of these interactions.¹¹ This can be a deciding factor for people on complex medication regimens. If you are taking several other drugs, rosuvastatin’s cleaner interaction profile is a genuine practical advantage.

Rosuvastatin is not completely free of interaction concerns. It is modestly metabolized by CYP2C9 and, as discussed, depends on drug transporters that can be inhibited by certain medications like cyclosporine. But the overall interaction burden is lighter than atorvastatin’s.

Cost and Adherence

Both rosuvastatin and atorvastatin are available as generics, which has leveled the playing field on cost. When Lipitor was still under patent and Crestor was brand-only, cost was a major factor pushing prescribers toward atorvastatin. Today, generic versions of both drugs are inexpensive, often costing under $10 per month at many pharmacies.

Adherence is the larger practical issue. Research on statin use patterns shows that patients treated with high-intensity regimens (which includes both high-dose rosuvastatin and high-dose atorvastatin) tend to stay on therapy longer than those on moderate or low-intensity regimens, with a median treatment duration of about 21 months versus 15 months.²⁴ The statin that works best is the one you actually take consistently, and factors like side effects, dosing convenience, and cost can matter more for long-term outcomes than milligram-for-milligram potency.

When Atorvastatin Is the Better Pick

Despite rosuvastatin’s advantages on lab numbers, there are scenarios where atorvastatin is clearly preferred. Patients with existing kidney disease or significant proteinuria are one such group, given atorvastatin’s more favorable renal profile. People taking multiple medications metabolized by drug transporters that interact with rosuvastatin, like cyclosporine in transplant patients, may also fare better on atorvastatin or need careful dose limits. And for patients of East Asian descent who want to avoid starting at a non-standard dose, atorvastatin avoids the pharmacogenetic wrinkle altogether.

There are also patients for whom it genuinely does not matter much which one they take. If you need a moderate intensity statin and are otherwise healthy with normal kidney function, both drugs will get you to goal, the side effect profile is similar, and the cardiovascular protection appears equivalent when LDL levels are matched. In that case, whichever is cheaper at your pharmacy or whichever you tolerate without muscle complaints is the pragmatic winner.

Brain Effects and Ongoing Debate

Some patients worry about statins and cognitive function. The FDA added a general warning about possible memory problems to all statin labels in 2012, but large-scale clinical evidence has not confirmed a meaningful effect in humans. One concern specific to the rosuvastatin-versus-atorvastatin comparison draws on the lipophilic/hydrophilic distinction. Lipophilic statins like atorvastatin can cross the blood-brain barrier more easily, which theoretically could affect brain cells. Hydrophilic statins like rosuvastatin should have a harder time getting in.

Animal research has shown that high-dose rosuvastatin can impair cognitive function in rats, with reduced levels of neurotrophic factors in the hippocampus.²⁵ But rat doses do not translate directly to human doses, and the existing human data on statins and cognition, whether hydrophilic or lipophilic, has not produced consistent evidence of harm. This remains an area where clinical opinions vary, and large definitive trials comparing cognition between the two drugs have not been done. If a patient reports new cognitive symptoms after starting either drug, a reasonable step is to try switching to the other or to a lower dose before abandoning statin therapy entirely.